
Cortexyme
VerifiedCortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases
Launch date
Employees
Ownership
Market cap
$58.3m
Net debt
-
Firm valuation
$304—456m (Public information from May 2018)
Share price
$1.95 CRTX
San Francisco California (HQ)
Deals in current and previous year: